Pharming buys rare disease drug from Novartis for $20mPharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis Share XPharming buys rare disease drug from Novartis for $20mhttps://pharmaphorum.com/news/pharming-buys-rare-disease-drug-from-novartis-for-20m/
Dutch biotech Pharming plans to challenge big pharma in rare diseasesThe introduction of Shire’s preventive treatment for hereditary angioedema has shaken up the market for drugs for this Share XDutch biotech Pharming plans to challenge big pharma in rare diseaseshttps://pharmaphorum.com/r-d/views-analysis-r-d/pharming-challenge-pharma-rare-diseases/
FDA rejects Pharming’s Ruconest HAE label expansionThe FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for Share XFDA rejects Pharming’s Ruconest HAE label expansionhttps://pharmaphorum.com/news/fda-rejects-pharmings-ruconest-hae-label-expansion/
